Get the Stockscreener App
9.82
4.66%
-0.48
Pre-market:
9.82
Replimune Group Inc stock is traded at $9.82, with a volume of 2.05M.
It is down -4.66% in the last 24 hours and up +12.74% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$10.30
Open:
$10.22
24h Volume:
2.05M
Relative Volume:
0.42
Market Cap:
$770.31M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-3.1076
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-4.84%
1M Performance:
+12.74%
6M Performance:
-3.06%
1Y Performance:
-23.52%
1-Day Range:
$9.79
$10.35
1-Week Range:
$9.79
$11.09
52-Week Range:
$2.68
$14.80
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
9.82 | 807.97M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq
Replimune Stock Presents a Complex Investment Narrative - AD HOC NEWS
Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group CEO Sushil Patel Sells 10,000 Shares - TradingView
CEO Patel Sells 10,000 ($111.3K) Of Replimune Group Inc [REPL] - TradingView
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Replimune Group, Inc. - The National Law Review
Will Replimune Group Inc. stock reach all time highs in 2025Oil Prices & Risk Managed Investment Strategies - BỘ NỘI VỤ
How Replimune Group Inc. stock trades during market volatility2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman (PR Newswire) - Aktiellt
What Is Driving Replimune Stock’s 98% Surge Today? - MSN
Can One97 Communications Limited Deliver Consistent Free Cash FlowsVolume Spike Alerts & Swing Trade Smarter With Data Insights - earlytimes.in
Replimune Group Inc. stock volume spike explainedWeekly Stock Analysis & Short-Term Trading Alerts - newser.com
How Replimune Group Inc. stock reacts to global recession fearsMarket Trend Review & Smart Investment Allocation Insights - newser.com
Replimune Group (NASDAQ:REPL) Insider Sells $47,392.80 in Stock - MarketBeat
Will Replimune Group Inc. stock deliver shareholder valueQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - newser.com
Using AI based signals to follow Replimune Group Inc.Bond Market & Long Hold Capital Preservation Tips - newser.com
Trend analysis for Replimune Group Inc. this weekWeekly Market Outlook & Low Volatility Stock Suggestions - newser.com
Replimune Group Executives Sell Shares for Tax Obligations - TradingView
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Why Replimune Group Inc. stock is a must watch in 2025July 2025 Levels & Weekly High Momentum Picks - newser.com
Smart tools for monitoring Replimune Group Inc.’s price actionWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Replimune Group Inc. stock benefit from AI adoption2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
How to use Fibonacci retracement on Replimune Group Inc.2025 Top Gainers & Risk Managed Trade Strategies - newser.com
Will Replimune Group Inc. stock deliver consistent dividendsEarnings Beat & Low Drawdown Investment Strategies - newser.com
How to build a custom watchlist for Replimune Group Inc.Weekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Replimune Group (REPL) Stock Analysis Report | Financials & Insights - Benzinga
How Replimune Group Inc. stock compares to growth peersTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
171,527 Shares in Replimune Group, Inc. $REPL Purchased by Candriam S.C.A. - MarketBeat
Replimune Group, Inc. (REPL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Replimune Group, Inc. (REPL) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What hedge fund activity signals for Replimune Group Inc. stockWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy - MSN
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):